Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Urcosimod - OKYO Pharma

Next Previous
Search
Drug Profile

Urcosimod - OKYO Pharma

Alternative Names: OK-101; OKYO-0101; OKYO-101

Latest Information Update: 19 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator On Target Therapeutics
  • Developer OKYO Pharma; Ora Inc
  • Class Anti-inflammatories; Antiallergics; Eye disorder therapies; Lipids; Non-opioid analgesics; Peptides
  • Mechanism of Action CMKLR1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dry eyes; Neuropathic pain
  • Preclinical Allergic conjunctivitis; Cytokine release syndrome; Ocular pain; Uveitis

Most Recent Events

  • 10 Mar 2025 OKYO Pharma submits a Fast Track designation application to the US FDA for Urcosimod for Neuropathic pain
  • 15 Oct 2024 Okyo Pharma initiates phase IIa trial for Neuropathic Pain in the USA (Ophthalmic, Drops) (NCT06637527)
  • 15 Oct 2024 Phase-II clinical trials in Neuropathic pain in USA (Ophthalmic), (NCT06637527),

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top